In this talk, Drs. Melissa Bondy, Lidia Schapira, and Stephanie Smith will provide an overview of the Population Sciences Program at the Stanford Cancer Institute. They will also highlight survivorship research studies across the lifespan and give examples of multidisciplinary collaboration, with an emphasis on research and clinical innovations relevant to pediatric, adolescent, and young adult cancer survivors.

ABOUT THE SPEAKERS

**Melissa Bondy, PhD** - Dr. Melissa Bondy is the inaugural chair of the Department of Epidemiology and Population Health, Co-Director of Center for Population Health Sciences, and the Associate Director for Population Sciences at the Stanford Cancer Institute. Before joining Stanford, she was Associate Director of Cancer Prevention and Population Sciences and section chair of Epidemiology and Population Sciences at Baylor College of Medicine. Her research focus is in genetic and molecular epidemiology and is at the forefront of developing innovative ways to assess the roles of heredity and genetic susceptibility in the etiology of cancer and outcomes, primarily brain and breast cancer. She has a strong interest in health disparities and has a current study to investigate the ethnic differences in glioma.

**Lidia Schapira MD, FASCO** - Dr. Lidia Schapira is Associate Professor of Medicine at Stanford University School of Medicine and Director of Cancer Survivorship at the Stanford Cancer Institute. She graduated from Dartmouth Medical School and trained at the Beth Israel Hospital in Boston in internal medicine and completed a hematology and oncology fellowship at the Brigham and Women's Hospital followed by a research fellowship in Aging at Harvard Medical School.

**Stephanie Smith, MD** - Dr. Stephanie Smith is an instructor in pediatric hematology/oncology at Stanford University School of Medicine. She completed fellowship in pediatric hematology/oncology at Stanford and previously trained in internal medicine and pediatrics at CHOP and Penn. She is passionate about the intersection between clinical care and clinical research and committed to understanding the long-term effects of childhood cancer therapies over the course of our patients’ lifetimes.